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Background and Purpose: 
Fentanyl overdose deaths have reached ‘epidemic’ levels in North America. Death in 
opioid overdose invariably results from respiratory depression. In the present work we 
have characterized how fentanyl depresses respiration and by comparing fentanyl with 
heroin and morphine, the active breakdown product of heroin, we have sought to 




Respiration (rate and tidal volume) was measured in awake, freely moving mice by 
whole body plethysmography 
 
Key Results 
Intravenously administered fentanyl produced more rapid depression of respiration 
than equipotent doses of heroin or morphine. Fentanyl depressed both respiratory rate 
and tidal volume. Fentanyl did not depress respiration in  opioid receptor knock-out 
mice. Naloxone, the opioid antagonist widely used to treat opioid overdose, reversed 
the depression of respiration by morphine more readily than that by fentanyl whereas 
diprenorphine, a more lipophilic antagonist, was equipotent in reversing fentanyl and 
morphine depression of respiration. Prolonged treatment with morphine induced 
tolerance to respiratory depression but the degree of cross tolerance to fentanyl was 
less than the tolerance to morphine itself.  
 




We propose that several factors (potency, rate of onset, lowered sensitivity to 
naloxone and lowered cross tolerance to heroin) combine to make fentanyl more likely 
to cause opioid overdose deaths than other commonly abused opioids. Lipophilic 
antagonists such as diprenorphine may be better antidotes than naloxone to treat 
fentanyl overdose. 
 
Bullet Point Summary 
What is already known 
• Fentanyl and related analogues are potent opioids responsible for many 
overdose deaths in intravenous opioid users in North America 
What this study adds 
• On intravenous administration fentanyl depresses respiration faster than 
heroin or morphine 
• Fentanyl depresses both respiratory rate and tidal volume 
• Naloxone is weaker at reversing fentanyl depression of respiration than that 
produced by morphine whereas diprenorphine reverses both equally. 
• Fentanyl breaks through tolerance to respiratory depression induced by 
prolonged morphine treatment 
What is the clinical significance 
• Fentanyls are more likely to cause overdose due to their fast rate of onset, 







Since 2013 there has been a dramatic rise in acute opioid overdose deaths involving 
new synthetic opioids, primarily the fentanyls (fentanyl and structurally related 
medicinal and illicit drugs), in North America (NIH, 2019). Of the over 60,000 opioid 
overdose deaths in the USA in 2017 almost 30,000 involved fentanyls, exceeding 
those involving heroin or prescription opioids such as oxycodone and hydrocodone. 
Elsewhere, in Europe, fentanyl deaths have been recorded in Estonia (for some time 
fentanyls were the main street opioids available in that country), and there have been 
sporadic outbreaks of fentanyl-related deaths in the UK, Germany and Finland 
(EMCDDA, 2018). Ease of synthesis (cf. the need to grow swathes of opium poppies 
to produce heroin), high potency (smaller quantities need to be shipped by comparison 
with heroin) and ease of purchase on the dark web make the fentanyls attractive to 
suppliers of illicit opioids (Fairbairn et al., 2017). Fentanyls are frequently mixed with 
heroin to increase its potency (Griswold et al., 2017; Marinetti et al., 2014). A recent 
development is the addition of fentanyls to cocaine products and to illicit prescription 
opioid and benzodiazepine tablets (Green and Gilbert, 2016; Sutter et al., 2017). 
Death in fentanyl overdose results primarily from depression of respiration (Mathers 
et al., 2013; Pierce et al., 2015). Fentanyls and other opioid agonists depress 
respiration by acting on  opioid receptors at various sites to reduce the response to 
raised pCO2 and lowered pO2 and thus reduce the drive to breathe (Pattinson, 2008). 
This reduction in respiratory drive results in a decrease in the rate of breathing and in 
periods of apnea (cessation of breathing) which in extremis results in death.  
 
A number of factors may contribute to why the fentanyls are so deadly. Their high 




thus even a small error in weighing out the drug can result in too much being taken. 
Rapid penetration into the brain can result in overdose levels being reached more 
quickly than with heroin. Deaths in heroin overdose may take more than 30 min to 
occur after injection (Darke et al., 2016), providing a window of opportunity for 
intervention (administration of the opioid antagonist naloxone). In contrast, fentanyl 
overdose deaths can occur very quickly before there is an opportunity to administer 
naloxone (Burns et al., 2016). Fentanyls induce muscle stiffness (Benthuysen et al., 
1986; Streisand et al., 1993) including in intercostal and diaphragm muscles, often 
referred to as ‘wooden chest’, and this is likely to make it harder to breathe. There 
have been several reports suggesting that depression of respiration by fentanyls 
shows reduced sensitivity to reversal by naloxone (Fairbairn et al., 2017; Lynn et al., 
2018; Peterson et al., 2016; Schumann et al., 2008). In one report, several cases were 
recorded in which multiple doses of naloxone were required before recovery of 
respiration following a fentanyl overdose (Somerville et al., 2017). Furthermore, a low 
level of cross tolerance between heroin and fentanyls may allow the fentanyls to retain 
potency to depress respiration in individuals tolerant to heroin-induced respiratory 
depression. In the present paper we have characterized how fentanyl depresses 
respiration in mice and have sought to determine how the factors described above 





METHODS AND MATERIALS  
 
Animals: Male CD-1 mice weighing approximately 30 g were obtained from Charles 
River (UK). Breeding pairs of  opioid receptor knock-out mice (Oprm1tm1Kff, stock 
number 007559) were obtained from the Jackson Laboratory (USA) and offspring bred 
in house at the University of Bristol. Both male and female  opioid receptor knock-out 
mice weighing between 25 and 30 g were used in this study. Male and female wild 
type C57BL/J mice weighing approximately 30 g were purchased from Charles River 
(UK). All mice were maintained at 22 °C on a reversed 12 h dark-light cycle with food 
and water available ad libitum. All experiments were performed in the dark (active) 
phase. Mice were randomly ascribed to treatment groups with the experimenter 
blinded to the drug treatment or knock-out/wild type phenotype as appropriate. 
 
All procedures were performed in accordance with the UK Animals (Scientific 
Procedures) Act 1986, the European Communities Council Directive (2010/63/EU) 
and the University of Bristol ethical review document, as well as the ARRIVE 
and British Journal of Pharmacology guidelines. 
 
Measurement of respiration: Respiration was measured in freely moving mice using 
plethysmography chambers (EMKA Technologies, France) supplied with a 5% CO2 in 
air mixture (BOC Gas Supplies, UK) as described previously (Hill et al., 2016; Hill et 
al., 2018). The day prior to experimentation mice were habituated to plethysmograph 
chambers for 30 min whilst breathing air. On the day of experimentation a 20 min 
baseline respiration period was recorded prior to administration of an opioid agonist 
challenge. Rate and depth of respiration were recorded and averaged over 1 or 5 min 




respectively) and converted to minute volume (rate x tidal volume). Tidal volume was 
calculated from the raw inspiration and expiration data in concert with compensation 
accounting for internal plethysmograph chamber variations in temperature and 
humidity as well as reference atmospheric pressure according to the Drorbaugh and 
Fenn Formula (Drorbaugh and Fenn., 1955). Drugs were administered i.v. or i.p. as 
indicated. Changes in body temperature induced by opioid agonists was not monitored 
during the plethysmography experiments. 
 
Measurement of locomotor activity: A beam break rig (Linton Instrumentation, UK) 
was used to assess the locomotor activity of mice. An automated data logging suite 
(AMON Lite, Linton Instrumentation, UK) was used to track the movement of mice 
throughout the experimental session. On the day prior to locomotor assessment each 
mouse was placed in a fresh cage and allowed to explore the cage for 30 min. On the 
experimental day the mouse was again allowed to explore the cage for 30 min before 
drug administration. Locomotor activity was then measured for 30 min following drug 
administration. Mice had access to water ad libitum but had no access to food in either 
session in order to dissuade rearing and climbing behaviour. 
 
Drug administration: In most experiments we have used i.p. injection as this is a 
simple and relatively non-stressful means of drug administration to mice. However, in 
those experiments designed to determine rate of onset of effect opioid agonist drugs 
were administered i.v. with mice restrained in a clear plastic tube while opioid or 





Reversal of opioid respiratory depression by opioid antagonists: Respiration was 
recorded for 20 min followed by an acute i.p. injection of opioid or vehicle. Respiration 
was then recorded for 20 min following opioid/vehicle administration, allowing maximal 
depression of respiration to occur. Naloxone or diprenorphine was then administered 
(20 min after opioid/vehicle) by i.p. injection on the opposite side of the peritoneal 
cavity to the opioid/vehicle injection.  
 
Induction of morphine tolerance: Tolerance to morphine respiratory depression was 
induced by 3x 100 mg.kg-1 morphine injections, administered 12 h apart followed by 
subcutaneous implantation of morphine-filled osmotic mini-pumps delivering 45 
mg.kg-1.day-1 morphine for a total of 6 d as described previously (Hill et al., 2016; Hill 
et al., 2018). Control mice were injected with saline and implanted with minipumps that 
were filled with saline. 
 
Experimental design and data analysis: Data from previous experiments where 
respiratory depression and locomotor activity were measured either following acute 
opioid administration in naïve mice or following pump implantation were subjected to 
post hoc power analyses using G*Power (version 3.1.9). Our calculations indicated 
that for depression of respiration n=6 (acute experiments) or n=7 (pump experiments) 
and for locomotor activity n=8 for each individual group would produce a significant 
result if an actual effect occurred. 
 
For each mouse the change in each behavioural parameter (respiratory rate, tidal 
volume, minute volume and locomotor activity) following acute drug administration has 




Hill et al., 2016; Hill et al., 2018; Withey et al., 2017). Area under the response versus 
time curve (AUC) was determined using a 100% baseline as described previously (Hill 
et al., 2016). Overall changes from a single factor were analysed using a One-way 
ANOVA with Bonferroni’s post-test. Statistical significance is assumed when P<0.05. 
Only where P<0.05 in One- or Two-way ANOVA analyses were post-hoc comparisons 
made between parametric variables. Data were excluded only where values were 
different by greater than two standard deviations from the mean (as outlined in the 
appropriate figure legends). GraphPad Prism 5 was used for all statistical analyses. 
All data are displayed as mean ± standard error of the mean (s.e.m.). The data and 
statistical analyses (on group sizes of n>5 where each n is an independent value) 
comply with the recommendations on experimental design and analysis in 
pharmacology (Curtis et al., 2018). 
 
Drugs and chemicals: Heroin hydrochloride (diacetyl morphine hydrochloride), 
morphine hydrochloride (both from Macfarlane Smith, UK), fentanyl citrate, naloxone 
hydrochloride, naltrindole hydrochloride and norbinaltorphimine dihydrochloride (all 
from Sigma Aldrich, UK) were dissolved in sterile saline. Diprenorphine (Tocris, UK) 
was dissolved in water by adding an equivalent amount of hydrochloric acid and 





Nomenclature of targets and ligands: Key protein targets and ligands in this article 
are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the 
common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY 
(Harding et al., 2018), and are permanently archived in the Concise Guide to 







Depression of respiration by fentanyl, heroin and morphine. 
To study the rate of onset of respiratory depression fentanyl, heroin and morphine, 
were administered i.v. to mice. Morphine (7.5 mg.kg-1), heroin (7.5 mg.kg-1) and 
fentanyl (112 g.kg-1) each depressed minute volume significantly, reaching 
approximately the same degree of respiratory depression 10 - 15 min after injection 
(Fig. 1A). Saline injection did not significantly alter respiration. The half-time to reach 
maximum depression of minute volume was determined for each agonist by fitting a 
single exponential curve (Fig. 1A). Fentanyl had the fastest rate of onset and morphine 
the slowest (Table 1). The rate of onset of respiratory depression correlated with the 
lipophilicity of each drug (Table 1). 
 
Both morphine and heroin depressed respiration by decreasing the rate of respiration, 
having no effect on tidal volume (Fig. 1B & C). As previously reported (Hill et al., 2016; 
Hill et al., 2018) , tidal volume was maintained due to the prolongation of inspiration 
by apneustic compensation. However, fentanyl depression of respiration resulted from 
both a decrease in the rate of respiration (Fig. 1B) and a decrease in tidal volume (Fig. 
1C). As the rate of onset of the decrease in rate of respiration was the same for both 
heroin and fentanyl (Fig. 1B) then the faster depression of minute volume by fentanyl 
(see Fig. 1A) seems likely to be due to the rapid decrease in tidal volume (Fig. 1C). 
 
We have previously demonstrated the dose-dependency of depression of respiration 
by morphine and oxycodone in mice breathing 5% CO2 in air (Hill et al., 2016; Hill et 
al., 2018). Heroin (1 - 90 mg.kg-1 i.p.) produced a dose-dependent depression of 




volume at the highest dose of 90 mg.kg-1 (Fig. 2C, F & G). The potency of heroin to 
depress minute volume was similar to that previously reported for morphine (Hill et al., 
2016). Fentanyl (0.05 - 1.35 mg.kg-1 i.p.) produced a dose-dependent depression of 
tidal volume, respiratory rate and minute volume (Fig. 2B, D, E, F & G). To depress 
minute volume fentanyl was approximately 70-fold more potent than heroin.  
 
Effects of fentanyl and heroin on locomotor activity 
In mice, at high doses, morphine and other  opioid receptor agonists increase 
locomotor activity (Hill et al., 2016; Lessov et al., 2003; Valjent et al., 2010). In the 
present study we examined the effect on locomotor activity of doses of heroin and 
fentanyl that produced similar levels of depression of respiratory rate (Fig 2E) and 
observed that heroin (90 mg.kg-1 i.p.) increased locomotor activity whereas, fentanyl 
(1.35 mg.kg-1 i.p.) decreased locomotor activity (Fig. 3). 
 
Antagonism of fentanyl depression of respiration 
It has been suggested that in overdose in humans the depression of respiration by 
fentanyl is less effectively reversed by naloxone compared to that by heroin (Peterson 
et al., 2016; Schumann et al., 2008; Somerville et al., 2017). To investigate antagonist 
reversal of opioid respiratory depression, we administered equipotent doses of 
morphine, the main active breakdown product of heroin, and fentanyl (10 mg.kg-1 and 
0.15 mg.kg-1 i.p. respectively) to mice, allowed maximal depression of respiration to 
develop over 20 min and then administered naloxone or diprenorphine. Naloxone (0.3 
mg.kg-1 i.p.) rapidly antagonised the depression of respiration induced by morphine, 
with full reversal being apparent 5 min after naloxone administration (Fig. 4A). In 
contrast, the same dose of naloxone did not fully reverse the respiratory depression 




respiratory depression induced by fentanyl (Fig. 4B) but did fully reverse respiratory 
depression induced by morphine. Only when naloxone (3 mg.kg-1 i.p.) was 
administered did full reversal of the respiratory depression induced by fentanyl occur 
(Fig. 4C), i.e. a 10-fold greater dose of naloxone was required to reverse fentanyl 
respiratory depression compared to that by an equi-potent dose of morphine. On the 
other hand, when naloxone (0.3 mg.kg-1 i.p.) was administered 20 min prior to fentanyl 
or morphine the response to either opioid was attenuated although the fentanyl 
response was less affected than that of morphine (Fig. 4F).  
 
In contrast to naloxone, diprenorphine (0.03 mg.kg-1 i.p.) reversed equipotent doses 
of morphine and fentanyl to the same degree (Fig. 4D). However, administration of a 
higher dose of diprenorphine (0.09 mg.kg-1 i.p.) more rapidly reversed morphine and 
fentanyl depression of respiration (Fig. 4E). 
 
Fentanyl has been reported to be a relatively selective agonist at  opioid receptors 
showing 100-fold and 400-fold higher affinity for the  opioid receptor over  and  
opioid receptors respectively (Toll et al., 1998). To examine the possibility that there 
may be a  opioid receptor component to fentanyl’s respiratory depressant activity we 
have assessed the ability of the  opioid antagonist naltrindole to prevent the effect of 
fentanyl on minute volume, respiratory rate and tidal volume in CD-1 mice. Pre-
treatment with naltrindole (10 mg.kg-1) failed to prevent the depression of minute 
volume, respiratory rate and tidal volume produced by fentanyl (1.35 mg.kg-1)(Fig. 5); 
indeed, naltrindole slightly potentiated the effect of fentanyl on tidal volume (Fig. 5C) 
but not on respiratory rate (Fig. 5B). Furthermore, pre-treatment of CD-1 mice with the 




administration did not affect the respiratory depressant effects of fentanyl (1.35 mg.kg-
1) (Fig. 5D, E & F). We have previously reported that this treatment with NorBNI 
prevented the antinociceptive response to the  opioid receptor agonist U69593 in the 
tail flick latency assay and that U69593 alone did not depress respiration (Hill et al., 
2018).  
 
Finally, we examined the ability of fentanyl to depress respiration in  opioid receptor 
knock-out mice (C57BL/J background strain). Administration of fentanyl (1.35 mg.kg-1 
i.p.) to the wild type background strain of mice depressed minute volume by ~80%, 
respiratory rate by ~60% and depressed tidal volume by ~30% (Fig. 5G, H & I). 
Administration of the same dose of fentanyl to  opioid receptor knock-out mice 
produced no depression of either minute or tidal volume (Fig. 5E and F). 
 
Interactions between heroin, morphine and fentanyl 
Opioid users are not thought to use fentanyl as their primary drug of choice, rather 
they predominantly use heroin to which fentanyl has been added to enhance the 
“quality” of a given batch of heroin (Ciccarone, 2009; Dasgupta et al., 2013). They are 
therefore likely to have already developed some degree of tolerance to heroin. We 
therefore investigated the degree of cross tolerance to fentanyl produced by prolonged 
pre-treatment with morphine, the main active breakdown product of heroin. In control 
mice that were implanted with a pump containing saline an acute challenge with 
morphine (10 or 90 mg.kg-1 i.p.) produced respiratory depression of 40% and 60% 
respectively, whereas in mice that had received prolonged pre-treatment with 
morphine the response to the 10 mg.kg-1 challenge dose of morphine was completely 




demonstrate that the morphine pre-treatment had produced significant tolerance. In 
contrast morphine pre-treated mice showed significantly less cross tolerance when 
challenged with fentanyl (Fig. 6C - F). At the lower challenge dose of fentanyl (0.15 
mg.kg-1) the depression of respiration was partially reduced but to a lesser extent than 
the equipotent challenge dose of morphine (Fig. 6C & E). At the higher challenge dose 
of fentanyl (1.35 mg.kg-1) respiratory depression was the same as in non-morphine 
treated animals (Fig. 6D & F). 
 
DISCUSSION 
In the present study we observed that in the mouse fentanyl more rapidly depressed 
respiration than heroin and that with fentanyl the depression of respiration involved 
both a decrease in the frequency of breathing and a decrease in tidal volume whereas 
with heroin only at the highest dose was a small effect on tidal volume observed. 
Fentanyl was approximately 70x more potent that heroin or morphine in depressing 
respiratory rate; we observed a similar relative potency of fentanyl and morphine to 
produce antinociception in the same mouse strain (Hill, 2019). We also observed that 
the depression of respiration by fentanyl required higher doses of the opioid antagonist 
naloxone to be reversed than did the depression induced by morphine, the active 
breakdown product of heroin. In contrast diprenorphine reversed fentanyl and 
morphine depression of respiration to the same extent. The depression of respiration 
by fentanyl is mediated by the  opioid receptor because it was not observed in  
opioid receptor knock-out mice (see also Schmid et al., 2017). Finally, prolonged pre-
treatment of mice with morphine produced less cross tolerance to fentanyl than the 





The higher in vivo potency of fentanyls compared to other opioids is well documented 
as a factor in their lethality. However, we observed in this study that fentanyl was not 
only approximately 70x more potent than morphine and heroin when depressing 
mouse respiration, but it also had a significantly faster rate of onset to depress 
respiration. A fast rate of onset has been reported in fentanyl-using human populations 
with fentanyl suggested to produce lethal respiratory depression as quickly as 2 min 
following injection (Burns et al., 2016; Green and Gilbert, 2016). This would make 
effective intervention with naloxone in fentanyl overdose more difficult to achieve. 
 
Schmid et al., (2017) have proposed that fentanyl’s ability to depress respiration 
results from it being an ‘arrestin biased’  opioid receptor agonist (i.e. it is better at 
recruiting and signalling through arrestin than activating G protein signalling) and that 
opioid depression of respiration is mediated by arrestin signalling as proposed by 
Raehal et al. (2005). We have previously reported that fentanyl does not exhibit 
arrestin bias in arrestin translocation and GTPS binding assays (McPherson et al., 
2010; Rivero et al., 2012). Furthermore, in transgenic mice in which all the 
phosphorylation sites on the C tail of the  opioid receptor had been mutated to alanine 
and which are therefore not phosphorylated by G protein receptor kinases (GRKs) and 
do not recruit and bind arrestins, fentanyl still depressed respiration (Kliewer et al., 
2019). This observation brings into question the concept that opioid depression of 
respiration is a function of arrestin signalling (Montandon and Slutsky, 2019).  
 
We have previously reported that in the mouse the depression of respiration by several 
 opioid receptor agonists, morphine, oxycodone and methadone, results from a 




volume (depth of breathing) (Hill et al., 2016; Hill et al., 2018; Withey et al., 2017). In 
the present study however, we observed that fentanyl depressed both respiratory rate 
and tidal volume whilst heroin was only observed to reduce tidal volume slightly at the 
highest dose tested. The decrease in tidal volume produced by fentanyl may result 
from an increase in respiratory muscle stiffness and/or changes in phrenic motor 
activity during inspiration expiration (Campbell et al., 1995). Both fentanyl and 
alfentanil have been reported to cause profound muscle stiffness in rodents by an 
action on  opioid receptors in the CNS (Weinger et al., 1991; Lui et al., 1993). 
Conversely, the hyper locomotor activity induced by heroin in mice may stimulate 
respiration and obscure any decrease in tidal volume. This would not occur with the 
high dose of fentanyl we tested as it reduced locomotor activity but may occur at lower 
doses which do enhance locomotor activity (Kleiwer et al., 2019; Varshneya et al., 
2019).  
 
The  opioid antagonist naltrindole potentiated the fentanyl depression of tidal volume 
and thus also minute volume, without affecting the depression of respiratory rate. We 
have previously reported that naltrindole does not alter the depression of minute 
volume by morphine or oxycodone (Withey et al., 2017). This would imply that the 
effect of naltrindole on fentanyl depression of tidal volume is not an off target effect as 
any such off target effect would be expected to be observed against all the opioid 
agonists. Rather it implies that the fentanyl depression of tidal volume involves the 
release of endogenous opioid(s) on to  receptors. Given the possible role of muscle 
stiffness in the depression of tidal volume it is interesting to note that that  opioid 






In man, intravenous administration of high doses of fentanyl and alfentanil produces 
skeletal muscle rigidity resulting in stiffness of the chest wall (Benthuysen et al., 1986; 
Streisand et al., 1993; Waller et al., 1981). Brain micro injection studies in rats have 
implicated several brain regions - locus coeruleus, basal ganglia, nucleus raphe pontis 
and periaqueductal grey - as sites of action of fentanyls to induce muscle rigidity 
(Blasco et al., 1986; Lui et al., 1989; Lui et al., 1990; Slater et al., 1987; Weinger et 
al., 1991; Widdowson et al., 1986) and have shown that it is mediated by activation of 
, and not  or  opioid receptors (Vankova et al., 1996). It is likely therefore that in 
humans intravenous injection of fentanyl results in both a decreased drive to breathe 
and a mechanical resistance to breathing both of which would contribute to overdose 
death (Burns et al., 2016). Signs of muscle rigidity have been observed in opioid 
injectors who have presumably injected illicit fentanyls at a supervised drug injection 
facility in Vancouver (Kinshella et al., 2018).  
 
Our finding that naloxone less readily reversed respiratory depression by fentanyl 
compared with morphine confirms reports from studies in humans that more naloxone 
may be required to reverse a fentanyl overdose compared to a heroin overdose 
(Fairbairn et al., 2017; Lynn et al., 2018; Peterson et al., 2016; Schumann et al., 2008; 
Somerville et al., 2017). In our study we allowed the depression of respiration by each 
agonist to reach maximum before naloxone was administered to mimic how the drugs 
would be administered in an overdose situation. Lower sensitivity of fentanyl to 
antagonism by naloxone cannot be explained simply by fentanyl having high affinity 
for the  opioid receptor given that under competitive conditions the degree of 




and concentration of the antagonist (Rang et al., 2016). Furthermore, the lipophilic 
opioid antagonist, diprenorphine, a non-selective opioid antagonist (Corbett et al., 
1993) used in veterinary medicine to reverse the tranquilizing effects of 
etorphine and carfentanil in large animals, reversed both fentanyl and morphine 
depression of respiration equally. Why diprenorphine is better at antagonising fentanyl 
than naloxone is unknown at present. We can speculate that, due to its higher 
lipophilicity, diprenorphine may exhibit a differential drug concentration effect in the 
vicinity of the plasma membrane as described previously for dopamine antagonists 
(Gherbi et al., 2018). Alternatively, fentanyl and diprenorphine may bind to the  opioid 
receptor in a manner distinct from morphine and naloxone, as reported for certain 
ligands at M2, M3 and M4 muscarinic receptors (Dror et al., 2013; Chan et al., 2018).  
 
We have previously demonstrated that tolerance develops to the respiratory 
depressant effects of  opioid receptor agonists such as morphine, oxycodone and 
methadone (Hill et al., 2016; Hill et al., 2018). In the present study we observed that 
when morphine pre-treated mice were challenged with either fentanyl or morphine the 
degree of cross tolerance to fentanyl was less than the tolerance to morphine itself. A 
similar reduced level of cross tolerance between fentanyl and morphine has been 
reported in studies of rodent locomotor activity (Brase 1986) and antinociception 
(Paronis and Holzman, 1992; Bobeck et al., 2019), although one study has reported 
equal cross tolerance between morphine and fentanyl on antinociception (Romero et 
al., 2010). Cross tolerance develops between drugs acting at the same receptor, but 
the degree of cross tolerance will depend upon agonist intrinsic efficacy. Fentanyl has 
higher intrinsic efficacy (McPherson et al., 2010) and so needs to occupy a smaller 




affected by the loss of  opioid receptor function - from either receptor desensitization, 
internalization or degradation – that underlies tolerance. The implication being that 
with opioid drug users fentanyl will be able to ‘break through’ tolerance induced by 




Our studies in mice indicate that in overdose by humans a number of factors may 
contribute to the high lethality of fentanyl. These include its high potency, rapidity of 
onset of action, depression of rate and depth of respiration, lower sensitivity to reversal 







R.H., W.L.D., E.K. and G.H. participated in research design.  
R.H. and R. S. performed the experiments.  
R.H., R.S. and G.H. analysed the data.  
R.H., W.L.D., E.K. and G.H. participated in writing the manuscript. 
Funding 
The work described in this paper was supported by a grant from NIH 
(RO1DA036975) to W.L.D. and G.H. The funder of the study had no role in the study 
design, data collection, data analysis, data interpretation or writing of the report. 
Acknowledgements 
We thank Ruby Fletcher for assistance with respiratory data analysis.  
Conflicts of interest 







Alexander SP, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA, et al. 
(2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled 
receptors. Br J Pharmacol 174 Suppl 1: S17-S129. 
Benthuysen JL, Smith NT, Sanford TJ, Head N, & Dec-Silver H (1986). Physiology of 
alfentanil-induced rigidity. Anesthesiology 64: 440-446. 
Blasco TA, Lee D, Amalric M, Swerdlow NR, Smith NT, & Koob GF (1986). The role 
of the nucleus raphe pontis and the caudate nucleus in alfentanil rigidity in the rat. 
Brain Res 386: 280-286. 
Bobeck EN, Schoo SM, Ingram SL, Morgan MM. (2019). Lack of antinociceptive cross-
tolerance with co-administration of morphine and fentanyl Into the periaqueductal gray 
of male sprague-dawley rats. J Pain [Epub ahead of print]. 
Brase DA (1986). Unequal opiate cross-tolerance to morphine in the locomotor-
activation model in the mouse. Neuropharmacology 25: 297-304. 
Burns G, DeRienz RT, Baker DD, Casavant M, & Spiller HA (2016). Could chest wall 
rigidity be a factor in rapid death from illicit fentanyl abuse? Clin Toxicol 54: 420-423. 
Campbell C, Weinger MB, Quinn M. (1995). Alterations in diaphragm EMG activity 
during opiate-induced respiratory depression. Respir Physiol. 100: 101-117. 
Chan HCS, Wang J, Palczewski K, Filipek S, Vogel H, Liu ZJ et al. (2018). Exploring 
a new ligand binding site of G protein-coupled receptors. Chem Sci. 9:6480-6489. 
Ciccarone D (2009). Heroin in brown, black and white: Structural factors and medical 





Corbett AD, Paterson SJ, Kosterlitz HW (1993). Selectivity of ligands for opioid 
receptors. Handbook of Experimental Pharmacology, 104: 645-680. 
Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MA, et al. 
(2018). Experimental design and analysis and their reporting II: updated and simplified 
guidance for authors and peer reviewers. Br J Pharmacol 175: 987–993. 
Darke S, & Duflou J (2016). The toxicology of heroin-related death: estimating survival 
times. Addiction 111: 1607-1613. 
Dasgupta N, Freifeld C, Brownstein JS, Menone CM, Surratt HL, Poppish L, et al. 
(2013). Crowdsourcing black market prices for prescription opioids. J Med Internet 
Res 15: e178. 
Dror RO, Green HF, Valant C, Borhani DW, Valcourt JR, Pan AC, et al. (2013). 
Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. 
Nature. 503:295-299. 
Drorbaugh JE, & Fenn WO. (1955). A barometric method for measuring ventilation in 
newborn infants. Pediatrics. 16: 81-87. 
EMCDDA (2018). Fentanils and synthetic cannabinoids: driving greater complexity 
into the drug situation. 
https://webarchiveorg/web/20190213103824/http://wwwemcddaeuropaeu/system/file
s/publications/8870/2018-2489-td0118414ennpdf Archived 13-2-19. 
Fairbairn N, Coffin PO, & Walley AY (2017). Naloxone for heroin, prescription opioid, 
and illicitly made fentanyl overdoses: challenges and innovations responding to a 




Gherbi K, Briddon SJ, CHarlton SJ. (2018). Micro-pharmacokinetics: quantifying local 
drug concentration at live cell membranes. Sci Rep. 8: 3479. 
Green TC, & Gilbert M (2016). Counterfeit medications and fentanyl. Jama Intern Med 
176: 1555-1557. 
Griswold MK, Chai PR, Krotulski AJ, Friscia M, Chapman B, Boyer EW, et al. (2017). 
Self-identification of nonpharmaceutical fentanyl exposure following heroin overdose. 
Clin Toxicol (Phila) 56: 37-42 
Harding SD, Sharman JL, Faccenda E, Southan C, Pawson, AJ, Ireland, S et al. 
(2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and 
expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucl Acids 
Res 46: D1091– D1106 
Hill R. (2019). Polydrug opioid abuse and mechanisms of tolerance to opioid 
respiratory depression. PhD thesis, University of Bristol. 
Hill R, Dewey WL, Kelly E, & Henderson G (2018). Oxycodone-induced tolerance to 
respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition. 
Br J Pharmacol 175: 2492-2503. 
Hill R, Lyndon A, Withey S, Roberts J, Kershaw Y, MacLachlan J, et al. (2016). Ethanol 
reversal of tolerance to the respiratory depressant effects of morphine. 
Neuropsychopharmacology 41: 762-773. 
Kinshella MLW, Gauthier T, & Lysyshyn M (2018). Rigidity, dyskinesia and other 
atypical overdose presentations observed at a supervised injection site, Vancouver, 




Kliewer A, Schmiedel F, Sianati S, Bailey A, Bateman JT, et al. (2019). 
Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and 
diminish tolerance but worsen opioid side effects. Nat Comm. 10: 367. 
Lessov CN, & Phillips TJ (2003). Cross-sensitization between the locomotor stimulant 
effects of ethanol and those of morphine and cocaine in mice. Alcohol Clin Exp Res 
27: 616-627. 
Lui PW, Lee TY, & Chan SH (1989). Involvement of locus coeruleus and noradrenergic 
neurotransmission in fentanyl-induced muscular rigidity in the rat. Neurosci Lett 96: 
114-119. 
Lui PW, Chang GJ, Lee TY, Chan SH. (1993). Antagonization of fentanyl-induced 
muscular rigidity by denervation of the coerulospinal noradrenergic pathway in the rat. 
Neurosci Lett. 157: 145-148. 
Lui PW, Lee TY, & Chan SH (1990). Involvement of coerulospinal noradrenergic 
pathway in fentanyl-induced muscular rigidity in rats. Neurosci Lett 108: 183-188. 
Lynn RR, & Galinkin JL (2018). Naloxone dosage for opioid reversal: current evidence 
and clinical implications. Ther Adv Drug Saf 9: 63-88. 
Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G et al. 
( 2016). Structure‐based discovery of opioid analgesics with reduced side 
effects. Nature 537: 185– 190. 
Marinetti LJ, & Ehlers BJ (2014). A series of forensic toxicology and drug seizure cases 
involving illicit fentanyl alone and in combination with heroin, cocaine or heroin and 




Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, & Hickman M (2013). 
Mortality among people who inject drugs: a systematic review and meta-analysis. Bull 
World Health Organ 91: 102-123. 
McPherson J, Rivero G, Baptist M, Llorente J, Al‐sabah S, Krasel C et al. ( 2010). μ‐
Opioid receptors: correlation of agonist efficacy for signalling with ability to activate 
internalization. Mol Pharmacol. 78: 756– 766. 
Montandon G, & Slutsky AS. (2019). Solving the opioid crisis: respiratory depression 
by opioids as critical end point. Chest. [Epub ahead of print]. 
NIH (2019). National drug overdose deaths. 
https://webarchiveorg/web/20190213103737/https://wwwdrugabusegov/related-
topics/trends-statistics/overdose-death-rates Archived 13-2-19. 
Paronis CA, & Holzman SG. (1992). Development of tolerance to the analgesic 
activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl 
in rats. J Pharmacol Exp Ther. 262: 1-9. 
Pattinson KT (2008). Opioids and the control of respiration. Br J Anaesth 100: 747-
758. 
Peterson AB, Gladden RM, Delcher C, Spies E, Garcia-Williams A, Wang Y, et al. 
(2016). Increases in fentanyl-related overdose deaths - Florida and Ohio, 2013-2015. 
Morb Mortal Wkly Rep 65: 844-849. 
Pierce M, Bird SM, Hickman M, & Millar T (2015). National record linkage study of 
mortality for a large cohort of opioid users ascertained by drug treatment or criminal 





Raehal KM, Walker JK, Bohn LM ( 2005). Morphine side effects in β‐arrestin 2 
knockout mice. J Pharmacol Exp Ther 314: 1195– 1201. 
Rang HP, Ritter JM, Flower RJ, & Henderson G (2016). Rang and Dale's 
Pharmacology, 8th Edition. Elsevier (London). 
Rivero G, Llorente J, McPherson J, Cooke A, Mundell SJ, et al. (2012). Endomorphin-
2: a biased agonist at the μ-opioid receptor. Mol Pharm. 82(2): 178-88. 
Romero A, Miranda HF, Puig MM. (2010). Antinociceptive effects of morphine, 
fentanyl, tramadol and their combination, in morphine-tolerant mice. Pharmacol 
BioChem Behav. 97: 363-9. 
Schmid CL, Kennedy NM, Ross NC, Lovell KM, Yue Z, Morgenweck J et al. 
(2017). Bias factor and therapeutic window correlate to predict safer opioid 
analgesics. Cell 171: 1165– 1175 
Schumann H, Erickson T, Thompson TM, Zautcke JL, & Denton JS (2008). Fentanyl 
epidemic in Chicago, Illinois and surrounding Cook County. Clin Toxicol (Phila) 46: 
501-506. 
Slater P, & Starkie DA (1987). Changes in limb tone produced by regional injections 
of opiates into rat brain. Naunyn Schmiedeberg's Arch Pharmacol 335: 54-58. 
Somerville NJ, O'Donnell J, Gladden RM, Zibbell JE, Green TC, Younkin M, et al. 
(2017). Characteristics of fentanyl overdose - Massachusetts, 2014-2016. Morb Mortal 
Wkly Rep 66: 382-386. 
Streisand JB, Bailey PL, LeMaire L, Ashburn MA, Tarver SD, Varvel J, et al. (1993). 
Fentanyl-induced rigidity and unconsciousness in human volunteers. Incidence, 




Sutter ME, Gerona RR, Davis MT, Roche BM, Colby DK, Chenoweth JA, et al. (2017). 
Fatal fentanyl: one pill can kill. Academic Emergency Medicine 24: 106-113. 
Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, et al. 
(1998). Standard binding and functional assays related to medications development 
division testing for potential cocaine and opiate narcotic treatment medications. NIDA 
Res Monogr 178: 440-466. 
Valjent E, Bertran-Gonzalez J, Aubier B, Greengard P, Herve D, & Girault JA (2010). 
Mechanisms of locomotor sensitization to drugs of abuse in a two-injection protocol. 
Neuropsychopharmacology 35: 401-415. 
Vankova ME, Weinger MB, Chen DY, Bronson JB, Motis V, & Koob GF (1996). Role 
of central mu, delta-1, and kappa-1 opioid receptors in opioid-induced muscle rigidity 
in the rat. Anesthesiology 85: 574-583. 
Waller JL, Hug CC, Jr., Nagle DM, & Craver JM (1981). Hemodynamic changes during 
fentanyl--oxygen anesthesia for aortocoronary bypass operation. Anesthesiology 55: 
212-217. 
Weinger MB, Smith NT, Blasco TA, & Koob GF (1991). Brain sites mediating opiate-
induced muscle rigidity in the rat: methylnaloxonium mapping study. Brain Res 544: 
181-190. 
Widdowson PS, Griffiths EC, & Slater P (1986). The effects of opioids in the 
periaqueductal grey region of rat brain on hind-limb muscle tone. Neuropeptides 7: 
251-258. 
Withey SL, Hill R, Lyndon A, Dewey WL, Kelly E, & Henderson G (2017). Effect of 

















Fentanyl 0.54 ± 0.09*¶ 3.62 
Heroin 1.70 ± 0.68*  1.48 
Morphine 4.64 ± 1.62 0.57 
 
Table 1. Rate of onset of opioid depression of respiration following i.v. 
administration and calculated lipid solubility values (ClogP) for opioid agonists. 
The data for the onset of respiratory depression for opioid agonists were fitted to a 
single exponential (see Fig. 1A) to obtain the t1/2 value for each opioid drug. Data are 
presented as the mean ± s.e.m; n = 12 for each drug. Statistical comparison was made 
by 1-way ANOVA with Bonferroni’s comparison. * indicates statistical difference 
(p<0.05) from morphine and ¶ indicates statistical difference (p<0.05) from heroin 







Figure 1. Rate of onset of opioid respiratory depression. Respiratory parameters 
were monitored in mice receiving i.v. injection of fentanyl (112 g.kg-1), heroin (7.5 
mg.kg-1) morphine (7.5 mg.kg-1) or saline. A. Fentanyl, heroin and morphine rapidly 
depressed minute volume (MV), the effect of the drugs reaching a similar steady state 
10 - 15 min post-administration. Data for each drug are fitted to a single exponential. 
B. Fentanyl, heroin and morphine depressed respiratory rate. C. Heroin and morphine 
had no effect on tidal volume (TV), whereas fentanyl significantly depressed tidal 
volume [F = 65.05 (dfn = 3, dfd = 704)].  A-C. Saline injection did not alter any of the 
respiratory parameters. All data presented as mean ± s.e.m. Statistical comparison in 
C was made by 2-way ANOVA with Bonferroni’s comparison. * indicates p<0.05 
compared to saline. n=12 for each group. 
 
Figure 2. Effect of heroin or fentanyl on mouse respiration. A. Heroin (1 - 90 
mg.kg-1, i.p.) dose-dependently depressed minute volume (MV). B. Fentanyl (0.05 - 
1.35 mg.kg-1, i.p.) dose-dependently depressed minute volume. C. Heroin only slightly 
depressed tidal volume (TV) at the highest dose tested (Data from one mouse have 
been excluded from all heroin 90 mg.kg-1 results due to the TV values being two 
standard deviations higher than the group mean). D. Fentanyl dose-dependently 
depressed tidal volume. In C [F = 13.07 (dfn = 4, dfd = 192)] & D [F = 58.33 (dfn = 3, 
dfd = 160)] statistical comparison was made by 2-way ANOVA with Bonferroni’s 
comparison. * indicates p<0.05 compared to saline pre-treated mice. n=6 for each 
group. In A & B statistical significance was observed for most time points for each 
dose of heroin and fentanyl but *s have been omitted for clarity as the size of effect of 




for fentanyl and heroin depression of respiratory rate (data presented as peak 
depression of respiratory rate as calculated from experiments shown in A & B). F. 
Dose-response curves for fentanyl and heroin inhibition of tidal volume (data 
presented as peak depression of tidal volume calculated from experiments shown in 
C & D). G. Left hand trace - control respiratory trace in the absence of opioid. Middle 
trace – at maximum respiratory depression by heroin 90 mg.kg-1. Right hand trace - at 
maximum respiratory depression by fentanyl 1.35 mg.kg-1.  
 
Figure 3. Change in mouse locomotor activity following heroin or fentanyl 
administration. A. Saline (i.p.), heroin (90 mg.kg-1 i.p.) or fentanyl (1.35 mg.kg-1 i.p.) 
were administered to mice and locomotor activity measured. Heroin caused a 
sustained increase in locomotor activity compared to saline, whereas fentanyl caused 
a decrease in locomotor activity compared to saline. B. Area under the curve (AUC) 
analysis of data in A. Statistical comparison in B made using 1-way ANOVA with 
Bonferroni’s comparison. * indicates p<0.05 compared to saline. n=8 for each group. 
 
Figure 4. Reversal of morphine and fentanyl respiratory depression by naloxone 
and diprenorphine. A-C Equipotent respiratory depressant doses of morphine (10 
mg.kg-1 i.p.) and fentanyl (0.15 mg.kg-1 i.p.) were administered to mice before 
naloxone administration 20 min after saline or opioid agonist. A. Naloxone 0.3 mg.kg-
1 i.p. fully reversed morphine respiratory depression, but fentanyl respiratory 
depression was unaffected (-43.8 ± 4.8% pre-naloxone vs -28.1 ± 7.8% post-naloxone 
p>0.05) [F = 55.3 (dfn = 2, dfd = 15)]. B. Naloxone 1 mg.kg-1 i.p. fully reversed 
morphine respiratory depression, whereas fentanyl was not reversed (-42.7 ± 5.4% 




C. Naloxone 3 mg.kg-1 i.p. fully reversed both morphine and fentanyl respiratory 
depression. D. Diprenorphine 0.03 mg.kg-1 i.p. reversed morphine and fentanyl 
respiratory depression to the same degree E. Diprenorphine 0.09 mg.kg-1 i.p. rapidly 
reversed both morphine and fentanyl respiratory depression back to baseline levels. 
All data presented as mean ± s.e.m. Statistical comparison of minute volume following 
naloxone administration made by 2-way ANOVA with Bonferroni’s comparison. * 
indicates p<0.05 compared to saline. n=6 for each group. 
 
Figure 5. Fentanyl depression of respiration results from activation of  opioid 
receptors. A, B & C. Pre-treatment with naltrindole (10 mg.kg-1 i.p.) 20 min prior to 
fentanyl (1.35 mg.kg-1 i.p.) injection did not prevent fentanyl depression of minute 
volume (A), respiratory rate (B) or tidal volume (C). Instead naltrindole pre-treatment 
significantly enhanced fentanyl depression of both minute volume and tidal volume. D, 
E & F. Pre-treatment with NorBNI (20 mg.kg-1 i.p.) 24 h prior to administration of 
fentanyl did not alter fentanyl-induced depression of minute volume (D), respiratory 
rate (E) or tidal volume (F). G. Administration of fentanyl (1.35 mg.kg-1 i.p.) significantly 
depressed minute volume in wild-type background strain mice (MOP wild Type), but 
there was no effect in  opioid receptor knock-out mice (MOP Knock Out) [F = 933 
(dfn = 1, dfd = 80)].  H. Fentanyl (1.35 mg.kg-1 i.p.) also depressed respiratory rate in 
wild type mice but there was no effect in  opioid receptor knock-out mice [F = 414.1 
(dfn = 1, dfd = 80)]. I. Fentanyl (1.35 mg.kg-1 i.p.) depressed tidal volume in wild type 
mice but there was no effect in  opioid receptor knock-out mice [F = 170.9 (dfn = 1, 
dfd = 80)]. All data presented as mean ± s.e.m. Statistical comparison made by 2-way 
ANOVA with Bonferroni’s comparison. * indicates p<0.05 compared to saline pre-





Figure 6. Cross tolerance to fentanyl following prolonged morphine 
administration.  A-B. Acute morphine challenge (10 or 90 mg.kg-1 i.p.) induced less 
respiratory depression in morphine-treated mice compared to saline-treated controls. 
C. Acute fentanyl challenge (0.15 mg.kg-1 i.p.) induced less respiratory depression in 
morphine-treated mice compared to saline-treated controls. D. Acute fentanyl 
challenge (1.35 mg.kg-1 i.p.) induced the same level of respiratory depression in 
morphine-treated mice as was observed in saline-treated controls. E-F. The 
depression of respiration by fentanyl challenge (0.15 and 1.35 mg.kg-1) was not 
reduced to the same extent as that by morphine challenge (10 or 90 mg.kg-1) in 
morphine-treated animals. All data presented as mean ± s.e.m. Statistical comparison 
made by 2-way ANOVA with Bonferroni’s comparison. E [F = 3.86 (dfn = 1, dfd = 24)] 
F [F = 25.7 (dfn = 1, dfd = 24)] * indicates p<0.05 compared to morphine. n=7 for each 
group. 
 
 
